The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...